INSM
INSMED Inc
$107.18
-2.15%
$23.7B
No data for this timeframe.
Vol
Market Cap$23.7B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (96%)
Inst. Holders10 funds
Inst. Value$6.9B
Inst. Activity2 buys / 2 sells
Insider Activity0B / 18S
Insider Net $-$13.3M
SEC Reports17
Recent Activity
May 21, 2026
short_volume
Short Volume: INSM — 58.7% short (0.7M / 1.2M)
Short: 730,482 | Exempt: 25 | TRF Vol: 1,244,669 | Short Ratio: 58.7% | Off-exchange volume (dark po
May 18, 2026
Insider
Lewis William sold 6,259 shares
Chair and CEO @ $30.46 ($190.6K)
May 18, 2026
Insider
Lewis William sold 5,753 shares
Chair and CEO @ $105.32 ($605.9K)
May 18, 2026
Insider
Lewis William sold 6,259 shares
Chair and CEO @ $0.00 ($0.00)
May 16, 2026
SEC
Morgan Stanley upgrades INSM to Overweight — PT $212 (+94%) as part of 7-firm cluster
ANALYST-UPGRADE — Impact 5/10
Apr 16, 2026
SEC
Barclays initiates coverage on INSM with an Overweight rating and $231 price target, implying 44% upside from the curren
ANALYST-UPGRADE — Impact 8/10
Apr 16, 2026
SEC
Morgan Stanley initiated a double upgrade to Overweight from Equal-Weight with a $212 price target, implying 32.3% upsid
ANALYST-UPGRADE — Impact 9/10
Inst.
NORGES BANK — NEW
2,910,971 shares ($506.6M)
Price Targets
$200.00
+86.6% upside
Strong Buy
Current $107.18
Low $140.00
Median $205.00
High $243.00
21 analysts
$140.00
$243.00
Analyst Ratings
9Strong Buy
18Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 14, 2026 | Truist Securities | MAINTAIN | Buy → Buy |
| May 8, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
| May 8, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
| May 8, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
| Apr 17, 2026 | Roth Capital | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.77 ▲ +1.6% | $-1.09 — $-0.58 | 55% YoY | 13 |
| Next Q | $-0.60 ▼ -3.3% | $-1.14 — $-0.35 | 66% YoY | 13 |
| Current FY | $-2.74 ▲ +1.9% | $-4.29 — $-1.84 | 57% YoY | 14 |
| Next FY | $0.40 ▼ -46.0% | $-1.91 — $1.64 | 115% YoY | 15 |
Latest Reports
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $3.7B | — |
| FMR LLC | $1.7B | ADD |
| NORGES BANK | $506.6M | NEW |
| BANK OF AMERICA CORP | $300.3M | ADD |
| MORGAN STANLEY | $284.0M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 18, 2026 | Lewis William | M | $190.6K |
| May 18, 2026 | Lewis William | SELL | $605.9K |
| May 18, 2026 | Lewis William | M | $0.00 |
| May 14, 2026 | Flammer Martina | SELL | $1.2M |
| May 13, 2026 | Flammer Martina | SELL | $504.0K |
10 institutional holders with $6.9B total value (41,356,652 shares) as of 2025-Q4. Top holders: VANGUARD, FMR, NORGES.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 21,076,344 | $3.7B | 52.9% | — |
| 2 | FMR LLC | 9,927,936 | $1.7B | 24.9% | ADD +80.3% |
| 3 | NORGES BANK | 2,910,971 | $506.6M | 7.3% | NEW |
| 4 | BANK OF AMERICA CORP /DE/ | 1,725,681 | $300.3M | 4.3% | ADD +61.1% |
| 5 | MORGAN STANLEY | 1,631,906 | $284.0M | 4.1% | ADD +69.3% |
| 6 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,027,355 | $178.8M | 2.6% | NEW |
| 7 | TWO SIGMA INVESTMENTS, LP | 962,156 | $167.5M | 2.4% | DOUBLED +105.2% |
| 8 | WELLS FARGO & COMPANY/MN | 586,651 | $102.1M | 1.5% | ADD +98.2% |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 25,900 | $4.5M | 0.1% | NEAR_EXIT -92.7% |
| 10 | Duquesne Family Office LLC | 1,481,752 | $257.9K | 0.0% | TRIM -38.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 2,910,971 | — | $506.6M | 2025-Q4 |
| MORGAN STANLEY | ADD | 963,631 | 1,631,906 | +69.3% | $284.0M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 352,887 | 25,900 | -92.7% | $4.5M | 2025-Q4 |
| Duquesne Family Office LLC | TRIM | 2,423,435 | 1,481,752 | -38.9% | $257.9K | 2025-Q4 |
| FMR LLC | ADD | 5,093,261 | 9,180,963 | +80.3% | $1.3B | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 1,251,337 | 2,016,406 | +61.1% | $290.4M | 2025-Q3 |
| UBS Group AG | DOUBLED | 383,454 | 1,732,039 | +351.7% | $249.4M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 376,508 | 772,780 | +105.2% | $111.3M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 259,207 | 513,849 | +98.2% | $74.0M | 2025-Q3 |
| NORGES BANK | EXIT | 1,934,899 | 0 | -100.0% | $0.00 | 2025-Q3 |
| FMR LLC | ADD | 3,394,384 | 5,093,261 | +50.0% | $512.6M | 2025-Q2 |
| NORGES BANK | NEW | — | 1,934,899 | — | $194.7M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 308,687 | — | $31.1M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 205,511 | 259,207 | +26.1% | $26.1M | 2025-Q2 |
| Duquesne Family Office LLC | ADD | 1,369,050 | 2,353,435 | +71.9% | $236.8K | 2025-Q2 |
| FMR LLC | TRIM | 4,856,249 | 3,394,384 | -30.1% | $259.0M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 593,996 | 406,903 | -31.5% | $31.0M | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | ADD | 160,709 | 205,511 | +27.9% | $15.7M | 2025-Q1 |
| Duquesne Family Office LLC | DOUBLED | 593,470 | 1,369,050 | +130.7% | $104.4K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 25,287 | 0 | -100.0% | $0.00 | 2025-Q1 |
| NORGES BANK | EXIT | 1,833,810 | 0 | -100.0% | $0.00 | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | ADD | 127,495 | 160,709 | +26.1% | $11.1M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 25,287 | — | $1.7M | 2024-Q4 |
| Duquesne Family Office LLC | DOUBLED | 20,000 | 593,470 | +2867.4% | $41.0K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 1,444,266 | — | $105.4M | 2024-Q3 |
12 unique insiders with 18 transactions. Net insider value: -$13.3M ($0.00 bought, $13.3M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 18, 2026 | Lewis William | Chair and CEO | M | 6,259 | $30.46 | $190.6K |
| May 18, 2026 | Lewis William | Chair and CEO | SELL | 5,753 | $105.32 | $605.9K |
| May 18, 2026 | Lewis William | Chair and CEO | M | 6,259 | $0.00 | $0.00 |
| May 14, 2026 | Flammer Martina M.D. | Chief Medical Officer | SELL | 10,479 | $117.54 | $1.2M |
| May 13, 2026 | Flammer Martina M.D. | Chief Medical Officer | SELL | 4,470 | $112.76 | $504.0K |
| May 13, 2026 | Smith Michael Alexander | Chief Legal Officer | SELL | 4,109 | $116.18 | $477.4K |
| May 13, 2026 | SHAROKY MELVIN MD | Director | A | 3,305 | $0.00 | $0.00 |
| May 13, 2026 | Adsett Roger | Chief Operating Officer | SELL | 5,837 | $116.18 | $678.1K |
| May 13, 2026 | Brennan David R | Director | A | 3,305 | $0.00 | $0.00 |
| May 13, 2026 | Desjardins Clarissa | Director | A | 3,305 | $0.00 | $0.00 |
| May 13, 2026 | LEE LEO | Director | A | 3,305 | $0.00 | $0.00 |
| May 13, 2026 | Lewis William | Chair and CEO | SELL | 13,283 | $116.18 | $1.5M |
| May 13, 2026 | ANDERSON ELIZABETH M | Director | A | 3,305 | $0.00 | $0.00 |
| May 13, 2026 | Bonstein Sara | Chief Financial Officer | SELL | 8,272 | $116.18 | $961.0K |
| May 13, 2026 | SCHAFER CAROL | Director | A | 3,305 | $0.00 | $0.00 |
| May 11, 2026 | Flammer Martina M.D. | Chief Medical Officer | M | 12,949 | $17.07 | $221.0K |
| May 11, 2026 | Flammer Martina M.D. | Chief Medical Officer | SELL | 12,119 | $100.35 | $1.2M |
| May 11, 2026 | Flammer Martina M.D. | Chief Medical Officer | M | 12,949 | $0.00 | $0.00 |
| May 4, 2026 | Lewis William | Chair and CEO | M | 6,259 | $0.00 | $0.00 |
| May 4, 2026 | Lewis William | Chair and CEO | SELL | 433 | $134.18 | $58.1K |
| May 4, 2026 | Lewis William | Chair and CEO | M | 6,259 | $30.46 | $190.6K |
| Apr 16, 2026 | Lewis William | Chair and CEO | M | 6,259 | $30.46 | $190.6K |
| Apr 16, 2026 | Lewis William | Chair and CEO | SELL | 2,246 | $142.99 | $321.2K |
| Apr 16, 2026 | Lewis William | Chair and CEO | M | 6,259 | $0.00 | $0.00 |
| Apr 6, 2026 | Lewis William | Chair and CEO | M | 6,259 | $0.00 | $0.00 |
| Apr 6, 2026 | Lewis William | Chair and CEO | M | 6,259 | $30.46 | $190.6K |
| Apr 6, 2026 | Lewis William | Chair and CEO | SELL | 787 | $161.73 | $127.3K |
| Apr 1, 2026 | Adsett Roger | Chief Operating Officer | M | 88,060 | $14.56 | $1.3M |
| Apr 1, 2026 | Adsett Roger | Chief Operating Officer | SELL | 6,715 | $163.18 | $1.1M |
| Apr 1, 2026 | Adsett Roger | Chief Operating Officer | M | 88,060 | $0.00 | $0.00 |
| Mar 30, 2026 | Smith Michael Alexander | Chief Legal Officer | SELL | 19,638 | $150.98 | $3.0M |
| Mar 30, 2026 | Smith Michael Alexander | Chief Legal Officer | M | 5,649 | $17.07 | $96.4K |
| Mar 30, 2026 | Smith Michael Alexander | Chief Legal Officer | M | 5,649 | $0.00 | $0.00 |
| Mar 19, 2026 | Lewis William | Chair and CEO | SELL | 1,629 | $142.17 | $231.6K |
| Mar 19, 2026 | Lewis William | Chair and CEO | M | 6,259 | $0.00 | $0.00 |
| Mar 19, 2026 | Lewis William | Chair and CEO | M | 6,259 | $30.46 | $190.6K |
| Mar 5, 2026 | Lewis William | Chair and CEO | M | 6,259 | $30.46 | $190.6K |
| Mar 5, 2026 | Lewis William | Chair and CEO | M | 6,259 | $0.00 | $0.00 |
| Mar 3, 2026 | SHAROKY MELVIN MD | Director | G | 100 | $0.00 | $0.00 |
| Feb 25, 2026 | SHAROKY MELVIN MD | Director | G | 1,072 | $0.00 | $0.00 |
| Feb 23, 2026 | Brennan David R | Director | G | 6,000 | $0.00 | $0.00 |
| Feb 19, 2026 | Lewis William | Chair and CEO | M | 6,259 | $30.46 | $190.6K |
| Feb 19, 2026 | Lewis William | Chair and CEO | SELL | 1,988 | $149.17 | $296.5K |
| Feb 19, 2026 | Lewis William | Chair and CEO | M | 6,259 | $0.00 | $0.00 |
| Feb 9, 2026 | Lewis William | Chair and CEO | M | 4,440 | $0.00 | $0.00 |
| Feb 9, 2026 | Lewis William | Chair and CEO | SELL | 4,888 | $147.17 | $719.4K |
| Feb 9, 2026 | Lewis William | Chair and CEO | M | 4,440 | $17.16 | $76.2K |
| Feb 9, 2026 | MCGIRR DAVID W J | Director | G | 53,400 | $0.00 | $0.00 |
| Feb 5, 2026 | Flammer Martina M.D. | Chief Medical Officer | SELL | 869 | $152.44 | $132.5K |
| Feb 3, 2026 | Adsett Roger | Chief Operating Officer | SELL | 791 | $156.17 | $123.5K |
17 SEC filing reports analyzed. Sentiment: 5 bullish, 3 bearish, 4 mixed, 5 neutral. Avg impact: 5.3/10.
BULLISH
ANALYST-UPGRADE
5/10
Morgan Stanley upgrades INSM to Overweight — PT $212 (+94%) as part of 7-firm cluster
May 16, 2026
BULLISH
ANALYST-UPGRADE
9/10
Morgan Stanley initiated a double upgrade to Overweight from Equal-Weight with a $212 price target,
Apr 16, 2026
BULLISH
ANALYST-UPGRADE
8/10
Barclays initiates coverage on INSM with an Overweight rating and $231 price target, implying 44% up
Apr 16, 2026
BULLISH
ANALYST-UPGRADE
7/10
Roth Capital initiates coverage on INSM with a Buy rating and $212 price target, implying 32.3% upsi
Apr 16, 2026
MIXED
ANALYST-UPGRADE
6/10
William Blair initiates coverage on INSM with an Outperform rating, adding to recent momentum that i
Apr 16, 2026
MIXED
ANALYST-UPGRADE
5/10
Jefferies initiates INSM with a Buy rating and $105 price target, below the $160.18 current price an
Apr 16, 2026
MIXED
ANALYST-UPGRADE
6/10
RBC Capital initiates coverage on INSM with Outperform and a $100 price target, below the $214.79 me
Apr 16, 2026
MIXED
ANALYST-UPGRADE
5/10
Truist Securities initiates coverage on INSM with a Buy rating and $48 price target, below the $214.
Apr 16, 2026
NEUTRAL
S-3ASR
3/10
Insmed filed an automatic shelf registration (S-3ASR) covering an indeterminate amount of common sto
May 15, 2026
NEUTRAL
CLUSTER
3/10
Two C-suite insiders (CMO and CLO) sold a total of ~$981K worth of INSM shares, representing a trivi
May 15, 2026
NEUTRAL
144
2/10
Sara Bonstein, an officer of Insmed, filed a Form 144 on May 13, 2026, indicating intent to sell 8,2
May 13, 2026
NEUTRAL
CLUSTER
3/10
Insmed's CEO and CMO sold a combined $1.27M in stock within a week of a strong Q1 2026 earnings beat
May 13, 2026
BULLISH
8-K
6/10
Insmed reported Q1 2026 total revenue of $306.0M (up 230% YoY, driven by BRINSUPRI launch) and a net
May 7, 2026
BEARISH
CLUSTER
7/10
Two C-suite executives at INSMED Inc sold shares in early April, generating $4.06M in open-market pr
Apr 8, 2026
BEARISH
8-K
7/10
Insmed announced that its Phase 2b CEDAR study of brensocatib in hidradenitis suppurativa (HS) faile
Apr 7, 2026
BEARISH
CLUSTER
5/10
Two C-suite executives at Insmed sold shares in the past week, generating $4.06 million in total pro
Apr 3, 2026
NEUTRAL
DEFA14A
3/10
Analysis based on filing metadata only — document content was unavailable
Apr 1, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (96% buy). Based on 28 analysts: 9 strong buy, 18 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$200.00 mean target
+86.6% upside
Strong Buy (1.23)
$140.00 Low
$243.00 High
| Metric | Value |
|---|---|
| Current Price | $107.18 |
| Target Low | $140.00 |
| Target Mean | $200.00 |
| Target Median | $205.00 |
| Target High | $243.00 |
| # Analysts | 21 |
| Recommendation | Strong Buy (1.23) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.77 | $-1.09 | $-0.58 | 54.6% | +1.6% | 4↑ 6↓ | $0.4B | 265.1% | 13 |
| Next Q 2026-09-30 |
$-0.60 | $-1.14 | $-0.35 | 66.0% | -3.3% | 4↑ 7↓ | $0.5B | 228.0% | 13 |
| Current FY 2026-12-31 |
$-2.74 | $-4.29 | $-1.84 | 57.3% | +1.9% | 5↑ 8↓ | $1.7B | 180.3% | 14 |
| Next FY 2027-12-31 |
$0.40 | $-1.91 | $1.64 | 114.7% | -46.0% | 3↑ 10↓ | $2.8B | 64.8% | 15 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.772 | |
| 7d ago | $-0.775 | +0.003 |
| 30d ago | $-0.784 | +0.012 |
| 60d ago | $-0.868 | +0.097 |
| 90d ago | $-0.825 | +0.053 |
16 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 14, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| May 8, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| May 8, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| May 8, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Apr 17, 2026 | Roth Capital | REITERATE | Buy | Buy |
| Apr 14, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Apr 1, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Mar 30, 2026 | Morgan Stanley | UPGRADE | Equal-Weight | Overweight |
| Mar 26, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 25, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Mar 24, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Mar 24, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Mar 24, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Mar 24, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Mar 23, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Feb 24, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Feb 23, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 20, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Jan 30, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
| Jan 28, 2026 | Barclays | INITIATE | — | Overweight |
| Jan 23, 2026 | Roth Capital | INITIATE | — | Buy |
| Jan 21, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Jan 6, 2026 | UBS | MAINTAIN | Buy | Buy |
| Dec 18, 2025 | TD Cowen | MAINTAIN | Buy | Buy |
| Dec 18, 2025 | Goldman Sachs | MAINTAIN | Buy | Buy |
| Dec 18, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Dec 18, 2025 | Guggenheim | MAINTAIN | Buy | Buy |
| Dec 18, 2025 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Dec 16, 2025 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Dec 16, 2025 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| Dec 15, 2025 | Goldman Sachs | MAINTAIN | Buy | Buy |
| Dec 11, 2025 | TD Cowen | MAINTAIN | Buy | Buy |
| Dec 1, 2025 | Mizuho | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 9 | 18 | 1 | 0 | 0 | 96% | |
| Apr 1, 2026 | 9 | 16 | 1 | 0 | 0 | 96% | |
| Mar 1, 2026 | 9 | 15 | 2 | 0 | 0 | 92% | |
| Feb 1, 2026 | 9 | 16 | 2 | 0 | 0 | 93% | |
| Jan 1, 2026 | 9 | 14 | 2 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 21, 2026
short_volume
Short Volume: INSM — 58.7% short (0.7M / 1.2M)
Short: 730,482 | Exempt: 25 | TRF Vol: 1,244,669 | Short Ratio: 58.7% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: INSM — 64.2% short (0.7M / 1.1M)
Short: 709,665 | Exempt: 334 | TRF Vol: 1,105,731 | Short Ratio: 64.2% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_volume
Short Volume: INSM — 57.7% short (1.6M / 2.8M)
Short: 1,603,238 | Exempt: 13 | TRF Vol: 2,780,528 | Short Ratio: 57.7% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings_calendar
INSM Q1 2026 Earnings Scheduled — 2026-05-07
May 6, 2026
short_volume
Short Volume: INSM — 62.3% short (0.5M / 0.8M)
Short: 476,618 | Exempt: 4,259 | TRF Vol: 765,237 | Short Ratio: 62.3% | Off-exchange volume (dark pool + OTC)
May 4, 2026
short_volume
Short Volume: INSM — 62.7% short (0.5M / 0.8M)
Short: 512,502 | Exempt: 90 | TRF Vol: 817,702 | Short Ratio: 62.7% | Off-exchange volume (dark pool + OTC)
Apr 28, 2026
short_volume
Short Volume: INSM — 56.2% short (0.3M / 0.5M)
Short: 298,836 | Exempt: 386 | TRF Vol: 531,317 | Short Ratio: 56.2% | Off-exchange volume (dark pool + OTC)
Apr 27, 2026
dark_pool
Dark Pool: INSM — 2.2M shares, 51,517 trades
Week starting 2026-04-27. Total ATS volume: 2,214,643 shares across 51,517 trades.
Apr 24, 2026
short_volume
Short Volume: INSM — 57.5% short (0.7M / 1.2M)
Short: 666,641 | Exempt: 2,338 | TRF Vol: 1,158,860 | Short Ratio: 57.5% | Off-exchange volume (dark pool + OTC)
Apr 23, 2026
Clinical Trial
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Phase Phase 3 — COMPLETED
Apr 23, 2026
clinical_trial_readout
Results Pending: Treprostinil Palmitil Inhalation Powder (Phase 3) — Completed 22d ago
Trial: An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-I
Apr 23, 2026
short_volume
Short Volume: INSM — 74.6% short (0.4M / 0.5M)
Short: 377,337 | Exempt: 410 | TRF Vol: 505,497 | Short Ratio: 74.6% | Off-exchange volume (dark pool + OTC)
Apr 22, 2026
short_volume
Short Volume: INSM — 76.8% short (0.5M / 0.6M)
Short: 482,491 | Exempt: 0 | TRF Vol: 627,927 | Short Ratio: 76.8% | Off-exchange volume (dark pool + OTC)
Apr 21, 2026
short_volume
Short Volume: INSM — 81.0% short (0.5M / 0.7M)
Short: 534,270 | Exempt: 0 | TRF Vol: 659,294 | Short Ratio: 81.0% | Off-exchange volume (dark pool + OTC)
Apr 20, 2026
dark_pool
Dark Pool: INSM — 2.8M shares, 49,186 trades
Week starting 2026-04-20. Total ATS volume: 2,762,941 shares across 49,186 trades.
Apr 20, 2026
short_interest
FTD: INSM — 139,933 shares ($20.2M) failed to deliver
Settlement: 20260420, Price: $144.48, FTD Value: $20,217,519.84, INSMED INC-NEW
Apr 1, 2026
Clinical Trial
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
Phase Phase 2 — COMPLETED
Mar 12, 2026
Clinical Trial
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis
Phase Phase 2 — COMPLETED
Feb 24, 2026
Clinical Trial
A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
Phase Phase 2 — ACTIVE_NOT_RECRUITING